Mereo BioPharma Group (MREO) Expected to Announce Earnings on Tuesday

Key Points

• Mereo BioPharma Group is expected to announce its Q2 2025 earnings on Tuesday, August 12th, with analysts predicting earnings of ($0.01) per share.
• Shares of Mereo BioPharma Group have recently traded up 1.5%, reaching $1.69, with a market capitalization of $267.92 million.
• Analysts have set a new average price target for Mereo BioPharma Group of $7.20, with ratings spanning from "sell" to "strong buy".

Mereo BioPharma Group (NASDAQ:MREO - Get Free Report) is projected to announce its Q2 2025 earnings results before the market opens on Tuesday, August 12th. Analysts expect Mereo BioPharma Group to post earnings of ($0.01) per share for the quarter.

Mereo BioPharma Group (NASDAQ:MREO - Get Free Report) last posted its earnings results on Tuesday, May 13th. The company reported ($0.02) EPS for the quarter, missing analysts' consensus estimates of ($0.01) by ($0.01). On average, analysts expect Mereo BioPharma Group to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Mereo BioPharma Group Stock Up 1.5%

Shares of Mereo BioPharma Group stock traded up $0.03 on Tuesday, reaching $1.69. 289,257 shares of the stock were exchanged, compared to its average volume of 1,756,700. The business has a 50 day moving average price of $2.34 and a two-hundred day moving average price of $2.45. The firm has a market capitalization of $267.92 million, a price-to-earnings ratio of -24.07 and a beta of 0.47. Mereo BioPharma Group has a twelve month low of $1.57 and a twelve month high of $5.02.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on MREO shares. Needham & Company LLC set a $5.00 target price on Mereo BioPharma Group and gave the stock a "buy" rating in a research report on Thursday, July 10th. Wall Street Zen downgraded shares of Mereo BioPharma Group from a "hold" rating to a "sell" rating in a research note on Friday, July 18th. One research analyst has rated the stock with a sell rating, four have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, Mereo BioPharma Group has an average rating of "Moderate Buy" and an average price target of $7.20.

Institutional Trading of Mereo BioPharma Group

A number of hedge funds and other institutional investors have recently modified their holdings of MREO. Goldman Sachs Group Inc. increased its stake in Mereo BioPharma Group by 0.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 2,125,920 shares of the company's stock worth $4,783,000 after buying an additional 6,068 shares during the period. Woodline Partners LP grew its holdings in shares of Mereo BioPharma Group by 53.2% during the first quarter. Woodline Partners LP now owns 947,986 shares of the company's stock worth $2,133,000 after buying an additional 329,202 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in shares of Mereo BioPharma Group by 62.6% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,569,100 shares of the company's stock worth $3,530,000 after buying an additional 604,200 shares in the last quarter. 62.83% of the stock is owned by hedge funds and other institutional investors.

Mereo BioPharma Group Company Profile

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.